Table 1 Baseline demographic and disease characteristics
Baseline characteristics | N = 91 |
|---|---|
Male,n(%) | 52 (57.1) |
Median age (range), years | 61.0 (35–87) |
ECOG PS,n(%) | |
0/1 | 88 (96.7) |
2 | 3 (3.3) |
CLL,n(%) | 82 (90.1) |
SLL,n(%) | 9 (9.9) |
Median time since initial diagnosis, months (range) | 39.4 (3.2–185.1) |
Number of prior lines of therapy | |
Median | 1.0 |
Min, max | 1, 9 |
≥ 2 prior lines of therapy, n (%) | 45 (49.5) |
Bulky disease,an(%) | 40 (44.0) |
Binet stage at study entry for CLL patientsb,n(%) | |
Stage A/B | 27 (32.9) |
Stage C | 55 (67.1) |
Ann Arbor stage at study entry for SLL patients,n(%) | |
Stage I | 1 (11.1) |
Stage III/IV | 8 (88.9) |
β2 microglobulin > 3.5 mg/L,n(%) | 68 (74.7) |
Unmutated IGHV,cn(%) | 51 (56.0) |
Del(17p) orTP53mutation,n(%) | 22 (24.2) |
Del(13q),n(%) | 41 (45.1) |
Del(11q),n(%) | 20 (22.0) |
Prior anticancer drug therapy,n(%)d | |
Alkylating agents (including bendamustine) | 68 (74.7) |
Nucleoside analogs | 52 (57.1) |
Anti-CD20-based therapy | 54 (59.3) |
Anti-CD20-based chemoimmunotherapy | 44 (48.4) |
Lenalidomide/thalidomide | 7 (7.7) |
Other therapies | 12 (13.2) |
Refractory to last systemic therapy,n(%) | 72 (79.1) |